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Immunophenotypic Characterization and Quantification of 
Neoplastic Bone Marrow Plasma Cells by Multiparametric Flow 
Cytometry and Its Clinical Significance in Korean Myeloma 
Patients 
Multiparametric flow cytometry (MFC) allows discrimination between normal and 
neoplastic plasma cells (NeoPCs) within the bone marrow plasma cell (BMPC) 
compartment. This study sought to characterize immunophenotypes and quantitate the 
proportion of NeoPCs in BMPCs to diagnose plasma cell myeoma (PCM) and evaluate the 
prognostic impact of this method. We analyzed the MFC data of the bone marrow 
aspirates of 76 patients with PCM and 33 patients with reactive plasmacytosis. MFC 
analysis was performed using three combinations: CD38/CD138/-/CD45; CD56/CD20/
CD138/CD19; and CD27/CD28/CD138/CD117. The plasma cells of patients with reactive 
plasmacytosis demonstrated normal immunophenotypic patterns. Aberrant marker 
expression was observed in NeoPCs, with negative CD19 expression observed in 100% of 
cases, CD56+ in 73.7%, CD117+ in 15.2%, CD27- in 10.5%, CD20+ in 9.2%, and CD28+ 
in 1.3%. In PCM patients, more than 20% of NeoPCs/BMPCs were significantly associated 
with factors suggestive of poor clinical outcomes. Patients who were CD27- or CD56+/
CD27-, demonstrated shorter overall survival than patients of other CD56/CD27 
combinations. Our results support the clinical value of immunophenotyping and 
quantifying NeoPCs in PCM patients. This strategy could help to reveal poor prognostic 
categories and delineate surrogate markers for risk stratification in PCM patients. 
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Oncology & Hematology
INTRODUCTION
The widespread use of multiparametric flow cytometry (MFC) 
and the increased availability of reagents for the surface and in-
tracellular staining of specific antigens have provided insights 
into the pathophysiology of plasma cell myeloma (PCM) that 
have improved our diagnostic and prognostic capabilities (1-3). 
Indeed, increasing evidence now exists in the literature for the 
potential clinical utility of MFC to immunophenotype plasma 
cells for the diagnosis of PCM or other plasma cell disorders (4-
15). 
 One key biological issue that remains to be addressed is how 
to use the number of infiltrating plasma cells to accurately mea-
sure the tumor burden during the initial staging of PCM pa-
tients. Recently, the European Myeloma Network published 
recommendations regarding the use of MFC to identify PCM 
markers and unequivocally identify plasma cells among other 
hematopoietic cells, as well as how to detect aberrant pheno-
types and distinguish normal cells from neoplastic plasma cells 
(NeoPCs) (16). However, no consensus has thus far been reached 
to quantitate the plasma cell burden. Consequently, the man-
agement of patients with plasma cell disorders is still far from 
becoming a routine practice in many clinical laboratories, de-
spite the demonstrated relevance of using MFC to evaluate PCM. 
 Here, we report the results of a recommended analytic strat-
egy that was performed on newly diagnosed PCM patients in a 
single center of Korea. The aim of the current study was to quan-
titate the proportion of NeoPCs within the overall bone marrow 
plasma cell (BMPC) compartment using MFC in order to esti-
mate tumor burden, and to compare the prevalence of patients 
with PCM and those with non-plasma cell disorders. In partic-
ular, we sought to determine whether the proportion of NeoPCs/ 
BMPCs could be used to predict the clinical outcomes of PCM 
patients. In addition, we also assessed the prognostic value of 
aberrant antigenic expression in myeloma cells.
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MATERIALS AND METHODS
Patients and samples
Diagnostic bone marrow (BM) samples were analyzed from 
109 patients with PCM (n = 76) or reactive plasmacytosis (n =  
33) between November, 2008 and April, 2010, at the Asan Medi-
cal Center (Seoul, Korea). A diagnosis of PCM was based on the 
criteria of the International Myeloma Working Group (17). Re-
active plasmacytosis was defined as having a percentage of 
BMPCs more than 3.0% without evidence of a plasma cell dis-
order. The conditions accompanying reactive plasmacytosis in-
cluded non-Hodgkin’s lymphoma, leukemia, myelodysplastic 
syndrome, and carcinoma. Patients with PCM included 40 men 
and 36 women (median age: 63.5 yr) and patients with reactive 
plasmacytosis included 20 men and 13 women (median age: 53 
yr). Table 1 shows the patient characteristics. At the time of writ-
ing, 15 patients (19.7%) had died. The median overall survival 
(OS) was 20.55 months (95% CI, 0.1-43.1 months), and a medi-
an follow-up period of 25.6 months for the survivors. 
Cytological examination by light microscopy 
BM was aspirated by iliac puncture and smears were directly 
prepared, air dried, and routinely stained using the Wright-Gi-
emsa procedure, according to standard protocols. Classical dif-
ferential counts of the BM smears were performed by a hema-
topathologist using light microscopy (LM) in order to identify 
plasma cells from a minimum of 500 consecutively nucleated 
cells in each preparation.
MFC evaluation
Immunophenotypic studies were performed within 24 hr of 
sample delivery to the laboratory in order to diagnose the BM 
aspirates. Immunophenotypic evaluation was performed using 
a flow cytometer (FACS Canto; BD Biosciences, Palo Alto, CA, 
USA). Whole erythrocyte-lysed BM samples were stained using 
the following 4-color surface combinations (FITC/PE/PerCP/
APC): CD38/CD138/-/CD45, CD56/CD20/CD138/CD19, and 
CD27/CD28/CD138/CD117. To assess the surface antigens, an 
aliquot of approximately 1 × 106 cells was labeled with pretitrat-
ed volumes of preconjugated monoclonal antibodies in accor-
dance with the manufacturer’s recommendations (BD Biosci-
ences). The cells were then washed with phosphate buffered 
saline and suspended in 1% paraformaldehyde. Acquisition 
was performed with at least 0.5-1 × 105 events per tube. Analy-
ses were carried out using the FACS Diva software (BD Biosci-
ences). Irrelevant isotype-matched antibodies were used to de-
termine the background fluorescence. Plasma cells were count-
ed based on the expression of CD138 and CD38. NeoPCs were 
categorized as having negative CD19 expression, weak or nega-
tive CD45 expression, or positive CD56 expression (Fig. 1). Tu-
mor burden (%) was calculated as: BMPC count measured by 
LM (%) × NeoPCs/BMPCs (as measured by MFC). 
 Aberrant immunophenotypes were defined to identify im-
munophenotypic criteria that could be used to differentiate re-
active forms of cells from NeoPCs. This included the expression 
of antigens not normally expressed (CD20, CD56, CD28, and 
CD117) and a lack of antigens that are normally expressed (CD19 
and CD27) by plasma cells in patients with reactive conditions. 
In patients with PCM, the expression of an antigen was consid-
ered positive when ≥ 20% of the plasma cells expressed it at the 
time of diagnosis.
 
Comparison of patient characteristics 
To evaluate the clinical usefulness of plasma cell immunopro-
filing, the clinical and laboratory characteristics determined at 
diagnosis were compared according to the percentage of NeoPCs. 
Data collected from each patient’s medical records included 
demographic data, the paraprotein isotype, various clinical and 
laboratory parameters at diagnosis, OS and progression-free 
survival (PFS). The reviewed laboratory parameters included 
serum calcium, serum creatinine, hemoglobin, serum M-pro-
tein, serum β2-microglobulin, serum albumin, serum C-reac-
tive protein (CRP), serum lactate dehydrogenase (LD), white 
blood cell (WBC) count, platelet count, the presence of Bence-
Jones proteinuria, differences between the involved/uninvolved 
free light chains (FLC) that were present in serum, plasma cell 
Table 1. Demographic and baseline characteristics of patients with plasma cell my-
eloma
Median value (range) or number (%)
Age (yr)  63.5 (43-85)
Male/Female 40/36 
M-protein subtypes
   IgG/IgA/IgD/light chain/non-secretory
   κ/λ/non-secretory
36/18/3/15/4
43/29/4
Calcium (mg/dL) 9.0 (7.1-12.3)
Creatinine (mg/dL) 1.0 (0.4-7.3)
Hemoglobin (g/dL) 9.85 (4.5-16.8)
Lytic bone lesion 57/75 (76.0)
β2-microglobulin (mg/L) 4.3 (1.5-21.7)
Albumin (g/dL) 3.2 (1.0-4.5)
CRP (mg/dL) 0.44 (0.03-33.5)
LD (IU/L) 221 (117-2769)
Bence-Jones proteinuria 32/73 (43.8)
FLC difference* 546.0 (2.9-68398.9)
Serum M-protein (g/dL) 1.35 (0.0-8.3)
ISS stage I/II/III 13/35/28
Extraosseous spread 11/75 (14.7)
Labeling index ≥ 3% 22/54 (40.7)
Plasmablastic morphology 21/75 (28.0)
High-risk cytogenetics 26/73 (35.6)
Treatment CT/CT+ASCT/Only supportive 33/30/13
*FLC difference is defined as the involved-uninvolved FLC isotype difference. PCM, 
plasma cell myeloma; CRP, C-reactive protein; LD, lactate dehydrogenase; WBC, white 
blood cell; FLC, free light chain; ISS, International Staging System; CT, chemotherapy; 
ASCT, autologous stem cell transplantation.
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labeling index, BMPC count (determined by LM), cell type of 
plasma cells (plasmablastic vs plasmacytic), and cytogenetics. 
The identification of high-risk cytogenetic abnormalities was 
based on the Mayo risk stratification criteria for myeloma (17). 
The reviewed clinical data included the presence of lytic bone 
lesions, extraosseous spread, clinical stage, and therapeutic mo-
dalities. Clinical staging for the PCM patients was performed 
according to the International Staging System (ISS), which is 
the most widely used method of assessing prognosis (17). Chro-
mosome analysis of the BM aspirates was also performed at di-
agnosis. 
Statistical analyses
Statistical analyses were performed using MedCalc (version 
12.3.0.0; MedCalc Software, Mariakerke, Belgium). Differences 
between nominal variables were evaluated using the chi-square 
test or Fisher’s exact test, and differences between continuous 
variables were evaluated using the Mann-Whitney U test. OS 
was measured from the diagnosis of PCM until death. PFS was 
measured from the start of treatment until disease progression 
or death (regardless of the cause of death), whichever came 
first. Survival curves were plotted according to the Kaplan-Mei-
er method and compared using the log-rank test. Multivariate 
analysis was performed using Cox modeling. A two-sided P val-
ue of < 0.05 was considered statistically significant. 
Ethics statement
The study protocol was approved by the institutional review 
board of Asan Medical Center (No. 2011-0227). This study was 
conducted in accordance with the Declaration of Helsinki. The 
Fig. 1. Gating strategy for the identification and quantification of neoplastic plasma cells. Plasma cells were gated based on low side scatter and the expression of CD138. Neo-
plastic plasma cells were characterized as CD56+, CD19-, and CD45weak or -.
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board waived the requirement for informed consent.
RESULTS
Quantification of plasma cells and NeoPCs by MFC 
Across the total cohort, we identified a median plasma cell per-
centage of 7.9% (range: 0.2%-83.5%) using MFC analysis, and 
15.0% (range: 3.0%-89.8%) using LM analysis, with a significant 
correlation observed between these 2 techniques (r = 0.806, 
P < 0.001). In patients with reactive plasmacytosis, the median 
plasma cell percentages determined using MFC and LM analy-
sis were 1.6% (range: 0.2%-6.5%) and 5.1% (range: 3.0%-31.4%), 
respectively, whereas in patients with PCM, the percentages 
were 16.4% (range: 0.9%-83.5%) and 31.6% (range: 4.8%-89.8%), 
respectively. 
 The median tumor burden, based on the number of NeoPCs/ 
BMPCs was 25.2% (range: 0.7%-89.7%) in PCM patients and 0% 
(range: 0%-0.1%) in patients with reactive plasmacytosis. The 
difference in tumor burden between the two patient groups 
was statistically significant (P < 0.001). Among PCM patients, 
36 patients (47.4%) demonstrated a high tumor burden (> 30%) 
whereas 19 patients (25.0%) demonstrated a low tumor burden 
(< 10%). Among those 19 patients, 11 patients (14.5%) demon-
strated very low tumor burden (< 5%). 
Frequency of aberrant immunophenotype in PCM 
patients
The plasma cells of the patients with reactive plasmacytosis 
demonstrated a normal immunophenotypic patterns (CD138+, 
CD19+, CD45+, CD27+, CD56-, and CD20-). For PCM patients, 
the overexpression of CD56, a marker involved in anchoring 
plasma cells to stromal structures, was found in 73.7% of cases 
(56 of 76). CD117, a tyrosine kinase receptor, and CD20, an an-
tigen associated with the early stages of B-cell maturation, were 
detected in 15.2% (5 of 33) and 9.2% (7 of 76) of cases, respec-
tively. However, CD28, an antigen associated with activated T 
lymphocytes, was present in only 1.3% (1 of 76) of patients. A 
lack of CD27 expression, an antigen involved in the differentia-
tion of mature B cells into plasma cells, was found in 10.5% (8 of 
76) of cases. The underexpression of CD19, an antigen present 
on all B cells and most normal plasma cells, was detected in ev-
ery patient (Fig. 2).
Impact of known parameters and MFC results on patients’ 
prognosis
The results of the Kaplan-Meier analysis indicated that patients 
with ISS stage II-III demonstrated significantly shorter OS times 
than patients with ISS stage I (P = 0.033; Table 2). Similarly, pa-
tients with ISS stage II-III demonstrated shorter PFS times than 
those with ISS stage I. However, the difference was not statisti-
cally significant according to the Kaplan-Meier analysis. Patients 
with high-risk cytogenetics, based on the Mayo risk stratification 
criteria for myeloma, also demonstrated significantly shorter 
OS and PFS times than those without (P < 0.001 and < 0.001, 
respectively). The Kaplan-Meier analysis revealed that other 
parameters, such as LD, IgA isotype, plasmablastic histology, 
and labeling index, did not influence OS or PFS, although pa-
tients with factors suggestive of adverse prognosis also demon-
strated shorter survival than those without these factors. One 
exception was that patients with the IgA isotype demonstrated 
significantly shorter OS than those with other isotypes (P = 0.033). 
According to the multivariate analysis, only high-risk cytogene-
tics was an independent prognostic factor associated with both 
decreased OS and PFS (hazard ratios, 5.9 and 5.5, P = 0.001 and 
< 0.001, respectively).
 With regard to the MFC results, tumor burden was divided 
into two groups (low burden and high burden) and evaluated 
until a significant difference in OS and PFS was observed. Un-
fortunately, the difference was not statistically significant at any 
cutoff point identified by the Kaplan-Meier analysis. Instead, 
patients with > 20% tumor burden demonstrated shorter OS 
and PFS times than those with tumor burden of ≤ 20% (medi-
ans of 18.15 vs 23.6 months for OS and 18.6 vs 25.4 months for 
PFS, respectively; Table 2). Patients with CD56 overexpression 
demonstrated shorter OS and PFS times than those without 
overexpression (medians of 18.85 vs 25.9 months for OS and 
20.55 vs 27.2 months for PFS, respectively), although the differ-
ences were not statistically significant according to the Kaplan-
Meier analysis (P = 0.219 and 0.513 for OS and PFS, respective-
ly) (Fig. 3A). Patients with CD27 underexpression also demon-
strated shorter OS and PFS times than those with CD27 overex-
pression (medians of 1.85 vs 23.55 months for OS and 13.7 vs 
24.6 months for PFS, respectively), but, again, these differences 
were not statistically significant (P = 0.246 and 0.245 for OS and 
PFS, respectively) (Fig. 3B). A combined analysis of CD56 and 
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Fig. 2. Frequencies of aberrant plasma cell immunophenotypes in patients with plas-
ma cell myeloma (PCM). Patients with PCM demonstrated aberrant immunopheno-
types in their plasma cells to varying degrees, while all patients with reactive plasma-
cytosis demonstrated plasma cells with normal immunophenotypes (CD138+, CD19+, 
CD45+, CD27+, CD56-, and CD20-).
Cho Y-U, et al. • Flow Cytometric Characterization and Quantification of Neoplastic Plasma Cells
546  http://jkms.org http://dx.doi.org/10.3346/jkms.2013.28.4.542
Table 2. Influence of prognostic factors on the survival times of patients with plasma cell myeloma
Prognostic factors No. Median OS* P value† No. Median PFS* P value†
ISS
  I
  II or III
13
63
33.2
13.2
0.033
13
47
32.8
17.5
0.229
Cytogenetics
  High-risk
  Other
26
47
7.65
25.6
< 0.001
19
40
9.0
27.8
< 0.001
Serum LD (IU/L)
  ≥ 300
  < 300
19
52
2.3
23.55
0.096
10
46
11.95
24.05
0.084
Plasma cell morphology  
  Plasmablastic
  Plasmacytic
21
54
17.5
22.6
0.285
16
44
15.6
24.0
0.105
Labeling index (%)
  ≥ 3
  < 3
22
32
18.9
13.5
0.610
17
25
19.7
15.6
0.864
M-protein isotype
  IgA
  Others
18
59
15.35
23.05
0.033
14
46
20.45
23.6
0.411
Tumor burden
  > 20%
  ≤ 20%
34
42
18.15
23.6
0.664
32
28
18.6
25.4
0.175
*Survival times (OS and PFS) are expressed in months; †P values are based on Kaplan-Meier survival curve analysis. OS, overall survival; PFS, progression-free survival.
Fig. 3. Median overall survival (OS) times of the patients with plasma cell myeloma. 
The Kaplan-Meier curve demonstrates the differences in the OS rates of two groups 
of patients, as defined by the expression of CD56 (A) and CD27 (B). The Kaplan-Mei-
er curve also demonstrates the difference in the OS rates between the two groups of 
patients, as defined by the combined expression of CD56 and CD27. Note the inter-
mediate survival times of patients with intermediate expression patterns (C).
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CD27 expression demonstrated better discrimination between 
longer and shorter survival times, although the Kaplan-Meier 
analysis did not indicate an overall statistical significance (P =  
0.102) (Fig. 3C). However, CD56+/CD27- patients demonstrat-
ed significantly shorter OS times than CD56-/CD27+ patients 
(medians of 5.35 vs 26.45 months, respectively; P = 0.045). Pa-
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tients with other combinations (CD56+/CD27+ or CD56-/CD27-) 
demonstrated intermediate survival times (Fig. 3C).
Relationship between the MFC results and disease 
characteristics
Because the NeoPCs/BMPCs ratio reflects the tumor burden 
for the patients with PCM, we sought to compare the disease 
characteristics of the two patient groups with high and low tu-
mor burdens, respectively. A tumor burden of > 20% was asso-
ciated with a significantly higher frequency of high-risk cytoge-
netics, lower hemoglobin level, lower WBC count, higher se-
rum M-protein level, higher FLC difference, and higher calcium 
level (Table 3). All of these features indicate the poor prognosis 
of PCM. The most significant association was observed between 
high tumor burden, as determined using the MFC assay, and 
high-risk cytogenetics (P < 0.001).
 The frequencies of high-risk cytogenetics and ISS stage III 
were not associated with CD56 expression. However, patients 
with CD27 underexpression were significantly associated with 
a higher frequency of high-risk cytogenetics (P = 0.045), but not 
ISS stage III. This association with high-risk cytogenetics was 
also observed in patients with CD56+/CD27-, although the sta-
tistical power was marginal (P = 0.061; Table 4).
DISCUSSION
The present data demonstrate the diagnostic and clinical utility 
of the characterization and quantification of NeoPCs by MFC 
for the assessment of patients with PCM. A high level of tumor 
burden, as determined by the ratio of NeoPCs/BMPCs, was as-
sociated with disease characteristics that imply a poor clinical 
outcome. In addition, CD27 underexpression or a combined 
pattern of CD56 and CD27 expression seemed to demonstrate 
a potential prognostic impact and were associated with high-
risk cytogenetics, an independent prognostic factor associated 
with shorter survival times. 
 Over the past 10 yr, MFC immunophenotyping has been in-
creasingly used for the diagnostic characterization and prog-
nostic stratification of patients with PCM. However, we still de-
pend on morphological features and immunohistochemical 
patterns to identify NeoPCs. While MFC has become part of the 
routine diagnostics for most hematologic malignancies in Ko-
rea, the use of MFC for the clinical management of PCM pa-
tients is not widespread. This is mainly attributed to the variable 
results observed for clinical correlations between PCM and the 
designated immunophenotypes of NeoPCs. Considering that 
MFC immunophenotyping can provide accurate assessment of 
the expression levels of multiple markers in thousands of plas-
ma cells and allows the clear discrimination between clonal 
and reactive plasma cells, the application of MFC for the evalu-
ation of PCM patients in Korea is vital. 
 In our study, the quantification of NeoPCs by MFC allowed 
us to discriminate between PCM and reactive plasmacytosis, 
with a high statistical power. It is normal for the BM aspirates 
from patients with reactive plasmacytosis to contain less Neo-
PCs as compared with that from PCM patients. Occasionally, 
however, extensive plasmacytosis may be indistinguishable 
from low-grade PCM in terms of morphology or the extent of 
plasma cell proliferation without using the M-protein analysis. 
Among our patients with reactive plasmacytosis, 4 patients 
were identified by LM examination as having more than 10% of 
plasma cells in their BM aspirate. Despite the high proportion 
of BMPCs identified in this subset of patients, which was above 
the diagnostic level for PCM, the amount of tumor burden as 
measured by MFC was definitely minimal. This finding strongly 
suggests that flow cytometric quantification of NeoPCs in PCM 
patients is clinically useful as a diagnostic marker and as a mark-
er for estimating tumor burden in PCM patients.
 Recently, risk stratification parameters for PCM were sug-
Table 3. Comparison of disease characteristics in terms of tumor burden in patients 
with plasma cell myeloma
Parameters
Tumor burden by MFC
P value
≤ 20% (n = 34) > 20% (n = 42)
Age (yr) 62 (43-85) 65.5 (43-75) 0.474
Male 19 (55.9) 21 (50.0) 0.780
Calcium (mg/dL) 8.8 (7.1-11.6) 9.2 (7.2-12.3) 0.038
Creatinine (mg/dL)  1.0 (0.4-5.0) 1.0 (0.5-7.3) 0.317
Hemoglobin (g/dL) 10.9 (7.9-16.8) 9.3 (4.5-13.9) 0.001
CRP (mg/dL) 0.89 (0.05-33.50) 0.34 (0.03-18.96) 0.076
LD (IU/L) 230.5 (117-1,634) 220 (127-2,769) 0.788
WBC ( × 109/L) 6.0 (4.0-36.9) 4.85 (2.3-13.3) 0.003
Platelet ( × 109/L) 196.5 (54-374) 181.5 (12-402) 0.389
FLC difference 199.6 (2.90-33,282.80) 789.2 (21.4-68,398.91) 0.027
Serum M-protein (g/dL) 0.6 (0.0-6.2) 2.8 (0.0-8.3) 0.013
ISS stage III 10 (29.4) 18 (42.9) 0.333
Extraosseous spread 5/33 (15.2) 6 (14.3) 0.707
Labeling index ≥ 3.0% 8/23 (34.8) 14/31 (45.2) 0.495
IgA 9 (26.5) 9 (21.4) 0.808
Plasmablastic  
  morphology
5 (14.7) 16 (38.1) 0.044
High-risk cytogenetics 3/33 (9.1) 23/40 (57.5) < 0.001
MFC, multiparametric flow cytometry; CRP, C-reactive protein; LD, lactate dehydroge-
nase; WBC, white blood cell; FLC, free light chain; ISS, International Staging System. 
Table 4. Comparison of high-risk cytogenetics, ISS stage III, and CD56 and CD27 ex-
pression patterns 
Expression patterns
High-risk 
cytogenetics (%)
P value ISS stage III (%) P value
CD56+ (n = 56)  
CD56- (n = 20) 
35.8
35.0
0.836 41.1
25.0
0.313
CD27- (n = 8)
CD27+ (n = 68)
75.0
31.7
0.045 62.5
33.8
0.229
CD56+/CD27- (n = 6)
CD56-/CD27+ (n = 18)
83.3
33.3
0.061 66.7
22.2
0.129
ISS, International Staging System. 
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gested, including ISS stage, cytogenetics, fluorescence in situ 
hybridization, LD, IgA isotype, plasmablastic histology, and la-
beling index (18). In addition to well-established prognostic 
factors, here we present tumor burden, as calculated from the 
NeoPCs/BMPCs ratio, as a potential prognostic marker. Al-
though its statistical significance for predicting patient survival 
was insignificant, tumor burden of more than 20% was associ-
ated with various prognostic factors that indicate poor clinical 
outcome, including high-risk cytogenetics, low hemoglobin 
level, low WBC count, high serum M-protein level, high FLC 
difference, and high calcium level. Among these factors, the as-
sociation with high-risk cytogenetics was the most significant. 
High-risk cytogenetics was an independent prognostic factor 
that was associated with adverse clinical outcomes in this study. 
This association strongly suggests the clinical significance of tu-
mor burden as determined using MFC as a prognostic marker. 
 A few previous studies have described the clinical usefulness 
of an approach like this, i.e., estimating tumor burden rather 
than studying specific antigen expression levels. Pérez-Persona 
et al. (6) investigated aberrant plasma cells/BMPCs as a marker 
for the risk of progression in 500 consecutive patients with mo-
noclonal gammopathy of uncertain significance (MGUS) or 
smoldering multiple myeloma (SMM). Patients with a marked 
predominance of aberrant plasma cells/BMPCs (≥ 95%) at di-
agnosis demonstrated significantly higher risks of progression 
in both MGUS and SMM. The multivariate analysis of PFS indi-
cated aberrant plasma cells/BMPCs ≥ 95% as the most impor-
tant independent variable. Paiva et al. (12) reported the prog-
nostic impact of the presence of > 5% normal plasma cells/
BMPCs at diagnosis in a large series of symptomatic PCM pa-
tients. Patients with symptomatic PCM and > 5% normal plas-
ma cells/BMPCs at diagnosis demonstrated a unique signature 
that was characterized by high hemoglobin levels, low levels of 
BMPCs, low levels of M-protein, low frequency of immune pa-
resis, and low frequency of high-risk cytogenetic abnormalities. 
In addition, this subgroup of patients also demonstrated a great-
er response rate to autologous stem cell transplantation and 
significantly longer OS and PFS rates.
 Multiple studies have reported the prognostic value of spe-
cific antigen expression patterns in NeoPCs. Besides CD45, an-
tigens with reported prognostic value include CD56, CD27, 
CD28, CD19, CD33, CD44, CD52, and CD117 (1-3). Among these, 
we analyzed the predictive influences of CD56 and CD27, be-
cause these antigens demonstrated sufficiently high expression 
levels to be used in a comparative analysis. Both antigens are 
associated with the clinical prognosis of PCM patients, but the 
expression patterns affecting clinical outcomes are contradic-
tory (1-3): CD56 expression is associated with poor clinical out-
comes, as is the lack of CD27 expression. Indeed, CD56 expres-
sion is associated with poor clinical outcomes in myeloma pa-
tients treated with conventional therapies while no such effects 
have been reported in other groups of patients who have re-
ceived autologous stem cell transplantation (1, 19, 20). The ex-
pression of CD27 is uniformly seen throughout normal plasma 
cells and plasma cells in MGUS. The progressive loss of CD27 
has been observed along with disease progression in PCM pa-
tients, and the lack of CD27 expression at diagnosis is associated 
with shorter OS times in PCM patients (1-3, 21, 22). Although 
our study did not confirm the prognostic value of these 2 anti-
gens using the Kaplan-Meier analysis, their expression patterns 
demonstrated a trend toward shorter survival times. In particu-
lar, CD27 underexpression demonstrated a clearer association 
with a lower OS than CD56 overexpression. CD27 underexpres-
sion was also significantly associated with high-risk cytogenetic 
abnormalities, which could be one of the underlying mecha-
nisms for the correlation between CD27 underexpression and a 
reduced OS. Interestingly, patients with a combination antigen 
CD56+/CD27- expression demonstrated lower survival times 
and were associated with high-risk cytogenetics as compared 
with CD56-/CD27+ patients. Furthermore, patients with other 
antigen combinations demonstrated intermediate OS times as 
compared with patients with CD56+/CD27- and CD56-/CD27+ 
expression. This suggests and reinforces the clinical relevance 
of these antigen combinations in patients with PCM.
 The major limitation of this study is that the study population 
was relatively small. We cannot completely exclude possible 
bias due to the small number of patients. We could not analyze 
the prognostic values or compare disease characteristics be-
sides CD56 and CD27 expression levels mainly due to the small 
number of patients. Secondly, the study participants were not a 
homogeneous group. Therefore, we cannot completely exclude 
the effect of therapeutic modalities on the clinical outcomes of 
our patients. In addition, the treatment of PCM has rapidly evol-
ved in the last decade. Despite these limitations, this is the first 
study to examine the clinical usefulness of the MFC assay for 
assessing PCM patients in Korea. This work might provide base-
line data for its use in future clinical trials that assess MFC in 
PCM patients in Korea. Due to the increasing occurrence of 
PCM in the Korean population (23), MFC immunophenotyp-
ing may be beneficial for diagnosis, prognostic stratification 
and the monitoring of minimal residual disease. Confirmation 
of the potential uses of the MFC assay for evaluating PCM war-
rants further studies that enroll large numbers of Korean patients.
 In conclusion, our results provide the biological and clinical 
basis for inmunophenotyping and quantifying NeoPCs in PCM 
patients. The present study reports the diagnostic and clinical 
value of tumor burden as calculated from NeoPCs/BMPCs, and 
the potential role of the expression patterns of CD27 and CD56/
CD27 combinations for the prognostic stratification in patients 
with PCM. Thus, MFC analysis can identify groups of patients 
with aggressive characteristics who could benefit from new treat-
ment modalities. We expect the MFC technique to be incorpo-
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rated into the routine evaluation and diagnosis of all PCM pa-
tients in the near future.
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